嘉应制药(002198) - 2025 Q1 - 季度财报

Revenue and Profitability - The company's revenue for Q1 2025 was ¥121,632,944.06, representing a year-over-year increase of 28.83% compared to ¥94,415,395.08 in the same period last year[5] - Net profit attributable to shareholders increased by 197.23% to ¥15,403,257.18 from ¥5,182,187.84 year-over-year[5] - The net profit after deducting non-recurring gains and losses surged by 315.11% to ¥15,751,018.59 from ¥3,794,433.53 in the previous year[5] - Basic earnings per share rose by 198.04% to ¥0.0304 from ¥0.0102 year-over-year[5] - Net profit for the current period was ¥15,403,257.18, representing a significant increase of 196.5% compared to ¥5,182,187.84 in the previous period[18] - Operating profit rose to ¥19,327,230.54, compared to ¥6,255,016.14, marking a 208.5% increase[18] - The total comprehensive income for the current period was ¥15,403,257.18, compared to ¥5,182,187.84 in the previous period, indicating strong growth[18] Assets and Liabilities - The company's total assets decreased by 3.12% to ¥812,635,918.09 from ¥838,820,451.71 at the end of the previous year[5] - Total assets decreased to ¥812,635,918.09 from ¥838,820,451.71, reflecting a reduction of approximately 3.1%[16] - Total liabilities increased to ¥88,487,902.21 from ¥80,599,696.61, indicating an increase of about 9.4%[15] - The company's total equity decreased to ¥724,148,015.88 from ¥758,220,755.10, a decline of approximately 4.5%[16] Cash Flow and Operating Activities - Cash flow from operating activities turned negative at -¥11,833,754.83, a decline of 193.73% compared to ¥12,624,935.63 in the same period last year[5] - Cash flow from operating activities showed a net outflow of ¥11,833,754.83, a decline from a net inflow of ¥12,624,935.63 in the previous period[19] - Cash and cash equivalents at the end of the period totaled ¥264,960,176.44, compared to ¥117,068,956.84 at the end of the previous period[20] - The company's cash and cash equivalents decreased to ¥264,960,176.44 from ¥336,141,154.38, representing a decline of approximately 21.2%[14] Accounts Receivable and Payable - Accounts receivable increased by ¥54,579,600, a growth of 70.89%, primarily due to revenue growth[11] - Accounts receivable increased significantly to ¥131,571,107.23 from ¥76,991,474.27, marking an increase of about 71.2%[14] - The company reported a significant increase in accounts payable, which rose to ¥11,606,617.68 from ¥12,607,576.55, a decrease of about 7.9%[15] Expenses - The company reported a significant increase in sales expenses, which rose by 33.84% to ¥4,417,000, attributed to revenue growth[11] - The company experienced a significant increase in sales expenses, which rose to ¥44,206,430.98 from ¥33,029,036.77, an increase of 33.9%[17] - Total operating costs amounted to ¥101,544,275.20, up from ¥89,135,396.31, reflecting a 13.5% increase[17] - Research and development expenses decreased to ¥1,699,113.63 from ¥2,031,024.37, a reduction of 16.3%[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,345, with the largest shareholder holding 10.28% of the shares[10] Product Development and Market Activity - The company has not reported any new product developments or market expansions during this period[12] - There are no indications of mergers or acquisitions in the recent financial disclosures[12]